Lymphoma research is moving forward in several distinct ways. The Coalition of Cancer Cooperative Groups highlights a few potential successes.
Vaccines
Several vaccines are now being evaluated in clinical trials, mostly for low-grade lymphoma. They are not intended to prevent lymphoma but to reduce the chance that a lymphoma will recur after treatment. In this type of vaccine treatment, doctors take a sample of an affected lymph node and use it to develop a vaccine. The lymphoma is then treated with chemotherapy. After the end of treatment, a series of injections of the vaccine are given, which may boost the body’s immunity against tumor cells. Results using this approach have varied and research is still continuing to make better vaccines.
Gene profiling
As scientists learn more about the genetics and the specific role that gene mutations play in cancer formation, they are better able to classify and diagnose subtypes of NHL. These techniques can help estimate prognosis for patients with certain types of lymphoma. These techniques are used primarily in lymphoma research, but in the next few years it is likely that therapies will be designed that work against specific genetic changes and counteract their effects.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...